Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.38 |
| ▸ | ODC1 | P11926 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA3 | P07451 | 2/20 | 0.30 |
| ▸ | CA4 | P22748 | 2/20 | 0.30 |
| ▸ | CA6 | P23280 | 2/20 | 0.30 |
| ▸ | CA5A | P35218 | 2/20 | 0.30 |
| ▸ | CA7 | P43166 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.30 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8057981 | 0.98 | DUT (0.37) | DUTODC1CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL29281207 | 0.98 | DUT (0.37) | DUTODC1NFKB1DNM1 | |
| SCHEMBL28903381 | 0.98 | DUT (0.37) | DUTODC1CA12CA1CA2 | |
| SCHEMBL100630 | 0.98 | DUT (0.37) | DUTODC1CA12CA1CA2 | |
| SCHEMBL8156589 | 0.98 | DUT (0.37) | DUTODC1CA12CA1CA2 | |
| SCHEMBL1038400 | 0.93 | ODC1 (0.42) | DUTODC1 | |
| SCHEMBL8063404 | 0.88 | DUT (0.43) | DUT | |
| SCHEMBL14245094 | 0.85 | DUT (0.42) | DUT | |
| SCHEMBL9007756 | 0.85 | DUT (0.42) | DUT | |
| SCHEMBL27241092 | 0.85 | DUT (0.42) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026047069-A1 | SYNTHESIS AND USE OF NOVEL DRIMANE SESQUITERPENOIDS OF KHAMKHAINE TYPE FROM THAI BASIDIOMYCOTA | OTTO-VON-GUERICKE-UNIVERSITÄT MAGDEBURG KÖRPERSCHAFT DES ÖFFENTLICHEN RECHTS (DE) | 2026-03-05 | — | — | WO | disclosed |
| EP-4698517-A1 | <SUP2/>? <SUB2/>?4?NOVEL COMPOUNDS AS ?? <NS1:SUB>7</NS1:SUB>?INHIBITORS | Evotec International GmbH (DE) | 2026-02-25 | — | — | EP | disclosed |
| US-20250340556-A1 | PYRIMIDOPYRIMIDONE COMPOUNDS AND METHODS OF USE THEREOF | SOLTEGO INC (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4526307-A1 | PYRIMIDOPYRIMIDONE COMPOUNDS AND METHODS OF USE THEREOF | Soltego, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2024218058-A1 | NOVEL COMPOUNDS AS α4β7 INHIBITORS | EVOTEC INTERNATIONAL GMBH (DE) | 2024-10-24 | — | — | WO | disclosed |
| EP-4396160-A1 | STEREOCHEMICALLY PURE LIPIDS FOR NUCLEIC ACID DELIVERY | Studiengesellschaft Kohle gGmbH (DE) | 2024-07-10 | — | — | EP | disclosed |
| CN-117881654-A | Stereochemically pure lipids for nucleic acid delivery | 科勒研究非盈利有限责任公司 | 2024-04-12 | — | — | CN | disclosed |
| WO-2023225097-A1 | PYRIMIDOPYRIMIDONE COMPOUNDS AND METHODS OF USE THEREOF | SOLTEGO, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023031210-A1 | STEREOCHEMICALLY PURE LIPIDS FOR NUCLEIC ACID DELIVERY | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2023-03-09 | — | — | WO | disclosed |
| US-11369586-B2 | Antifungal peptoids | Middle Tennessee State University (US) | 2022-06-28 | — | — | US | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20110124630-A1 | STEMONAMIDE SYNTHESIS INTERMEDIATE AND PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF CANCER | NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY (JP) | 2011-05-26 | — | — | US | disclosed |
| EP-2322528-A1 | STEMONAMIDE SYNTHESIS INTERMEDIATE AND PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF CANCER | National University Corporation Kanazawa University (JP) | 2011-05-18 | — | — | EP | disclosed |
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| EP-2049484-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008008022-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | WO | disclosed |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| US-6953785-B2 | Estra-1,3,5(10)-triene derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-10-11 | — | — | US | disclosed |
| US-20030216362-A1 | Estra-1,3,5 (10)-triene derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
| EP-1284272-A1 | ESTRA-1,3,5(10)-TRIENE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340556-A1 | PYRIMIDOPYRIMIDONE COMPOUNDS AND METHODS OF USE THEREOF | SIK2, SIK1, SIK3 | DUT 899/4885ODC1 1318/4885NFKB1 1722/4885 |
| US-20030216362-A1 | Estra-1,3,5 (10)-triene derivatives | STS, SULT1E1, SULT1A1 | DUT 1178/4885ODC1 2388/4885NFKB1 3039/4885 |
| US-11369586-B2 | Antifungal peptoids | ERG28, DPM1, QPCTL | DUT 1823/4885ODC1 2020/4885NFKB1 4170/4885 |
| US-20110124630-A1 | STEMONAMIDE SYNTHESIS INTERMEDIATE AND PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF CANCER | SULT1E1, CCNE1, SULT1A1 | DUT 206/4885ODC1 1077/4885NFKB1 2214/4885 |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | KCNH1, KCNH2, KCNH3 | DUT 2853/4885ODC1 1293/4885NFKB1 3001/4885 |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | DUT 619/4885ODC1 465/4885NFKB1 3263/4885 |
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | KCNH1, KCNH2, KCNQ2 | DUT 1596/4885ODC1 2120/4885NFKB1 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.